醒脑静注射液联合阿替普酶治疗急性缺血性脑卒中的临床研究

Abstract
Figure/Table
References (24)
Related Citation (15)

Download: PDF (806 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Xingnaojing Injection combined with Ateplase in the treatment of acute ischemic stroke. Methods From March 2015 to March 2019, a total of 86 patients with acute ischemic stroke admitted to 3201 Hospital Affiliated to Medical College of Xi′an Jiaotong University were selected. They were divided into the control group and the study group according to the random number table method, with 43 cases in each group. The control group was treated with Alteplase, while the study group was treated with Xingnaojing Injection on the basis of the control group. The clinical efficacy, inflammatory factors, internal carotid artery blood flow, degree of nervous functional defects, daily activity ability and adverse reactions of the two groups were compared. Results The total effective rate of the study group after treatment was significantly higher than that of the control group, and the difference was statistically significant (P ＜ 0.05). There was no statistically significant difference in interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and high-sensitivity C-reactive protein (hs-CRP) between the two groups of patients before treatment (P ＞ 0.05). After treatment, IL-6, TNF-α and hs-CRP of patients in both groups decreased compared with before treatment, and those in the study group were lower than those in the control group, the differences were statistically significant (P ＜ 0.05). The blood flow of basilar artery, anterior, middle and posterior cerebral artery and vertebral artery of patients of the two groups before treatment showed no significant difference (P ＞ 0.05). After treatment, the blood flow of basilar artery, anterior, middle and posterior cerebral artery and vertebral artery increased of patients in both groups, and those in the study group were higher than the control group, the differences were statistically significant (P ＜ 0.05). There was no significant difference in the score of neurological deficit degree (NIHSS), the score of modified Barthel index (mBI) between the two groups of patients (P ＞ 0.05). After treatment, the NIHSS score of patients of the two groups decreased compared with that before treatment, while the mBI score increased compared with that before treatment. After treatment, the NIHSS score of the study group was lower than that of the control group, while the mBI score was higher than that of the control group, the differences were statistically significant (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions of patients between the two groups (P ＞ 0.05). Conclusion Xingnaojing Injection combined with Alteplase in the treatment of acute ischemic stroke has a definite effect, can effectively improve the level of inflammatory factors and internal carotid artery blood flow, and has a good safety, with certain clinical application value.

Key words： Xingnaojing Injection Adverse reactions Acute ischemic stroke Clinical efficacy Ateplase

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIANG Jianjun1 TANG Rong1 LI Hua2 LIANG Yong2 XU Fei1

Cite this article:

LIANG Jianjun1 TANG Rong1 LI Hua2 LIANG Yong2 XU Fei1. Clinical study of Xingnaojing Injection combined with Alteplase in the treatment of acute ischemic stroke[J]. 中国医药导报, 2020, 17(2): 148-151,159.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I2/148

[1] Zhao L，Wang L，Lu M，et al. Hyperglycemia is associated with poor in-hospital outcome in elderly patients with acute ischemic stroke [J]. Medicine （Baltimore），2019，98（31）：e16723.
[2] Leite KKA，Sassi FC，Medeiros GC，et al. Clinical swallowing prognostic indicators in patients with acute ischemic stroke [J]. Arq Neuropsiquiatr，2019，77（7）：501-508.
[3] 常红，王晓娟.阿替普酶静脉溶栓治疗急性缺血性脑卒中出血并发症发生时间的观察[J].中华护理杂志，2014， 49（10）：1191-1193.
[4] 卜建宏，王长德，王岗，等.中国急性缺血性脑卒中急诊诊治专家共识中医救治解读[J].中国急救医学，2018，38（11）：941-945.
[5] 李宏图，杜春林.醒脑静注射液治疗急性缺血性脑卒中意识障碍的疗效观察[J].西部医学，2015，27（3）：410-411.
[6] 邢岩.中国急性缺血性脑卒中诊治指南2010[J].中国临床医生，2011，2（3）：50-59.
[7] 国家中医药管理局.中医内科病证诊断疗效标准（十三）[J].湖北中医杂志，2002，24（4）：封三.
[8] 展倩丽，孟繁军，田小燕.急性缺血性脑卒中患者血清淀粉样蛋白A及胱抑素C水平与病情程度相关性研究[J].疑难病杂志，2014，13（6）：573-575.
[9] 王建军，邹达良，区健刚，等.急性脑卒中患者血浆中脑钠肽的临床研究[J].中国医药指南，2014，12（14）：84-85.
[10] 许行飞，刘书来.奥扎格雷联合依达拉奉治疗急性缺血性脑卒中的临床疗效观察[J].黑龙江医药，2014，27（6）：1342-1343.
[11] 焦黛妍，邓海鹏，顾和燕，等.针刺结合西医常规疗法治疗脑卒中后抑郁临床研究[J].国际中医中药杂志，2017， 39（12）：1065-1068.
[12] Hayashi K，Morofuji Y，Horie N，et al. Progression of Endovascular Treatment for Acute Ischemic Stroke [J]. No Shinkei Geka，2019，47（7）：761-767.
[13] 王军，曹艳，常江，等.红景天苷对急性缺氧性神经细胞损伤保护作用及机制探讨[J].陕西医学杂志，2017，46（6）：706-708.
[14] Dillon GM，Stevens S，Dusenbury WL，et al. Choosing the Correct "-ase" in Acute Ischemic Stroke：Alteplase, Tenecteplase, and Reteplase [J]. Adv Emerg Nurs J，2019，41（3）：271-278.
[15] 贾爱明，谭婧，胡文梅，等.缺血性脑卒中复发的体质因素及中医诱因[J].中国老年学杂志，2014，34（9）：2435-2437.
[16] 张波.醒脑静注射液治疗缺血性脑卒中的临床观察[J].中国药房，2016，27（6）：755-757.
[17] Burgos AM，Saver JL. Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke [J]. Stroke，2019，50（8）：2156-2162.
[18] 刘海超，单勇，刘旸，等.醒脑静注射液辅助运动想象训练治疗缺血性脑卒中并上肢偏瘫患者的临床疗效及其对上肢功能的影响[J].实用心脑肺血管病杂志，2018， 26（11）：71-74.
[19] 孙梅芬，周丽丽.醒脑静注射液联合阿托伐他汀钙胶囊治疗急性脑出血的临床效果分析[J].中国现代医生，2018，56（3）：97-99.
[20] 刘小英，侯玉立.颈内动脉内中膜厚度与经颅多普勒脉动指数在缺血性脑卒中患者中的相关性分析[J].中西医结合心脑血管病杂志，2015，13（2）：258-259.
[21] 热娜·阿不都萨拉木，肖克来提·霍加合买提，李吉明，等.经颅多普勒超声在缺血性脑卒中患者急诊溶栓治疗中的应用[J].中国医药，2018，13（1）：63-66.
[22] 陈国宁，林泽辉，杜永明，等.丹参川芎嗪注射液对缺血性脑卒中患者同型半胱氨酸、高敏C反应蛋白和血脂水平的影响及疗效观察[J].中国医药导报，2018，15（1）：76-79.
[23] 奥婷，张芹，肖淑英，等.HMGB1与缺血性脑卒中关系的研究进展[J].医学综述，2018，24（9）：1681-1686.
[24] 刘润，周农.老年男性缺血性脑卒中患者炎性因子血清学水平变化与预后的关系[J].中国全科医学，2014，17（7）：795-799，809.